Celerion gets USP 797 OK for Ph I cleanroom

By Gareth Macdonald contact

- Last updated on GMT

Related tags: Clinical trial, Pharmacology

US CRO Celerion is to expand in-house compounding for microtracer studies after gaining certification for cleanroom and pharmacists at its Ph I unit in Lincoln, Nebraska.

The certification, covered by United States Pharmacopoeia (USP) guideline 797 on sterile preparations, allows the firm to offer compounding for medium and high risk candidates, whereas previously it was only able to handle low risk compounds.

Celerion spokeswoman Farzana Azam told Outsourcing-pharma.com that this in-house capability “Is a unique service in North America that is not offered by our peers which will save clients both time and money.

Previously our Sponsors needed to arrange for external manufacturing and sterilization to facilitate delivery of the sterile drug to the clinic where we would conduct the clinical protocol accordingly under a separate contract.

She explained that, in practice, this meant having to manage multiple contracts and obtain certificates of analysis (CoA) from several vendors, costing the sponsor additional time and money.

Today our sponsors would be able to hold one contract with Celerion. They would be able to ship their API and we would be able to prepare the drug on site and transfer the sterile solution to the clinical floor for administration according the protocol​.”

Celerion employs two full time pharmacists at the Lincoln facility, both of whom also received training in USP <797> requirements for compounding procedures and sterilisation methods from BAXA and PCCA.

The microdosing expansion is one of a number of additions early-phase trials specialist Celerion has made to its business since its launch following the break up of MDS Pharma Services in 2010.

In June​ the firm added hybrid ECG core laboratory capabilities to streamline the process of heart monitoring in early phase clinical trials.

More recently​ it partnered with BryanLGH Health System to add extra capacity for first in human trials at the Lincoln site, citing growing industry and regulatory demand for “in hospital” Phase I studies.

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

Related suppliers

Follow us


View more